Tuberc Respir Dis.
2007 Feb;62(2):144-148. 10.4046/trd.2007.62.2.144.
Acute Respiratory Failure Developed in Non-small Cell Lung Cancer Patients Treated With Gefitinib
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, Inha University, Incheon, South Korea. jsryu@inha.ac.kr
- 2Department of Pathology, College of Medicine, Inha University, Incheon, South Korea.
- KMID: 2114603
- DOI: http://doi.org/10.4046/trd.2007.62.2.144
Abstract
- Gefitinib is an oral selective inhibitor that targets the tyrosine kinase of the epidermal growth factor receptor. The prevalence of interstitial lung disease is 2% in Japan and 0.3% in the USA with a mortality rate of up to one third. We describe two non-small cell lung cancer patients who developed acute respiratory failure after gefitinib, and suggest that clinicians take extreme caution when deciding to treat patients with gefitinib.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Gefitinib-induced Acute Fatal Respiratory Failure in a Woman who Never Smoked and had Adenocarinoma of the Lung with EGFR Mutation
- A case of leptomeningeal metastasis from adenocarcinoma of the lung improved by treatment with Gefitinib
- The Effectiveness of Gefitinib on Spinal Metastases of Lung Cancer: Report of Two Cases
- Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
- Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
